Clinical Trial Update: Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Velcade (bortezomib) and Eloxatin (oxaliplatin) for malignant pleural or peritoneal mesothelioma. The current status of the trial is un…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Peritoneal Mesothelioma
• Malignant Pleural Mesothelioma

Drugs mentioned

• Eloxatin (oxaliplatin)
• Velcade (bortezomib)

Snippet

Sponsor: Columbia University | Conditions: Mesothelioma | Phase 2 | Status: UNKNOWN